LOX-1 Is a Novel Therapeutic Target in Neonatal Hypoxic-Ischemic Encephalopathy

• DOI: 10.1016/j.ajpath.2014.02.022
• Publication Date: 2014-04-13T10:03:28Z
• Authors: Tomohisa Akamatsu; Hongmei Dai; Masashi Mizuguchi; Yu-ichi Goto; Akira Oka; Masayuki Itoh
• Keywords: Hypoxic-Ischemic Encephalopathy; Hypoxia

Neonatal hypoxic-ischemic encephalopathy (HIE) remains a serious burden in neonatal care. Hypothermia provides good outcome some babies with HIE. Here, we investigated the biological mechanisms of its neuroprotective effect and sought for new therapeutic target. We made HIE rats subjected them to hypothermia at 28°C 3 hours. pathologically confirmed efficacy against brain. To clarify molecular mechanism hypothermia's efficacy, analyzed mRNA expression, immunoassay, pathology brain or without and/or hypothermia. selected from these analyses 12 molecules possible effects. After identification lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) as target candidate, examined an anti-LOX-1 neutralizing antibody rats. Administration reduced infarction area, edema, apoptotic cell death degree comparable Protection those pathological conditions was considered part The administering similar that LOX-1 is promising HIE, inhibition may become novel treatment who have experienced asphyxia.